Différences entre les versions de « Marco Ruggiero »
Aller à la navigation
Aller à la recherche
| Ligne 17 : | Ligne 17 : | ||
== Liens externes == | == Liens externes == | ||
| − | + | * http://scholarlyoa.com/2014/07/24/would-you-take-a-cancer-cure-proven-effective-in-a-predatory-journal/<br>I am writing this blog post in hopes of starting a conversation in the scientific community about the medicine called [[GcMAF]] and one of the companies that is currently distributing it, a company called GcMAF.eu<br><br>[[GcMAF]] means “Gc protein-derived macrophage activating factor,” according to the short article about it on Wikipedia. The drug is currently being marketed as a cure for many ailments, including cancer, autism, MS and Parkinson’s disease.<br><br>I am concerned about this drug and its marketing for these reasons:<br>1. Apparently, some of the same people who are researching the drug also are involved in marketing and selling it.<br>2. Some (not all) of their research has been published in questionable journals, including one published by a publisher that is on my list.<br>3. The drug is not approved by any competent authority (FDA, EMA) to treat any disease.<br><br>The following three articles report favorably on [[GcMAF]] and appear in the American Journal of Immunology a journal published by Science Publications, a publisher on my list. The three articles are:<br>1.Thyer, L., Ward, E., Smith, R., Branca, J. J. V., Morucci, G., Gulisano, M., [[David Noakes|Noakes, D.]] & Pacini, S. (2013). Therapeutic effects of highly purified de-glycosylated [[GcMAF]] in the immunotherapy of patients with chronic diseases. American Journal of Immunology, 9(3), 78-84.<ref>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738989/ Article "Therapeutic effects of highly purified de-glycosylated [[GcMAF]] in the immunotherapy of patients with chronic diseases"</ref><br>2.Smith, R., Thyer, L., Ward, E., Meacci, E., Branca, J. J. V., Morucci, G., Gulisano, M. R., Ruggiero, M., Pacini, A, Paternostro, F., Di Cesare Mannelli, L., [[David Noakes|Noakes, D. J.]], & Pacini, S. (2013). Effects of Gc-macrophage activating factor in human neurons; implications for treatment of chronic fatigue syndrome. American Journal of Immunology, 9(4), 120-129.<ref>http://thescipub.com/PDF/ajisp.2013.120.129.pdf Article "Effects of Gc-macrophage activating factor in human neurons; implications for treatment of chronic fatigue syndrome"</ref><br>3.Ward, E., Smith, R., Branca, J. J. V., [[David Noakes|Noakes, D.]], Morucci, G., & Thyer, L. (2014). Clinical Experience of Cancer Immunotherapy Integrated with Oleic Acid Complexed with De-Glycosylated Vitamin D Binding Protein. American Journal of Immunology, 10(1), 23-32.<ref>http://www.legamberifoods.com/polopoly_fs/1.155809.1411607941!/httpFile/file.pdf Article "Clinical Experience of Cancer Immunotherapy Integrated with Oleic Acid Complexed with De-Glycosylated Vitamin D Binding Protein"</ref><br><br>The first and the third articles report the authors’ experience with patients treated at the Immuno Biotech Treatment Center. From their website one sees that the cost is €6,000 a week for the center, and their hotel cost estimate is €1,800. This price is significantly higher than the €600 they charge for the [[GcMAF]] ampule alone. These patients have been an important source of revenue for this company.<br><br>As far as I can tell, none of the authors discloses affiliation to this center, so it is not clear who treated the patients. Moreover, there is no other information on this treatment center than the information on these articles and the website of this company. Thus it is rather strange that patients have to have a separate budget for their accommodation, which means there are being treated as outpatients. What is the point on making them travel to receive a treatment that could be given on an outpatient basis by one of the 350 doctors around the world claimed to be using [[GcMAF]]?<br><br>The publisher of the journal, Science Publications, lists two addresses on its “Contact Us” page, one in Adelaide, SA, Australia and one in New York, NY, USA. I think both addresses are really those of mail-forwarding services and the publisher is hiding its true location, which remains unknown.<br><br>Why are these scientists publishing their work in a highly questionable journal operated by a non-transparent publisher? If the work is so groundbreaking (a cure for cancer, et al.), why not publish it in a legitimate journal where its impact would be greater, its conclusions more convincing?<br><br>Do any of the authors have any declarable conflicts of interest? If so, what are they? Where can I find them?<br><br>On the [[GcMAF]].eu website, the site of the company that sells the potion, under the “Who we are” link, it says this:<br><br>We are a group of scientists led by Professor Marco Ruggiero MD, a molecular biologist and fully qualified medical doctor. The team includes a PhD and two BSc biomedical scientists. External doctors, oncologists and scientists kindly provide help and advice. We are committed to bringing [[GcMAF]] and its associated treatments to as many people as we can.<br><br>Ruggiero is listed as one of the authors of one of the articles above, so I assume the other authors are part of his team and are associated with the company [[GcMAF]].eu.<br><br>One of the first scientists to research [[GcMAF]] was Nobuto Yamamoto, but his 2007 article on the compound was retracted.<br><br>Regarding pricing, the company’s website states<br><br>Our GcMAF is €600, plus €60 packing and shipping, for one 2.2ml vial. A vial is one third full and contains up to eight doses – one 100ng, 0.25ml dose a week.<br><br>I found the overall tone of the GcMAF website to be mean and self-righteous. It makes a lot of claims such as “Root canals are a major cause of the immune system being suppressed and they are a major cause of cancer.”<br><br>Is the published science behind [[GcMAF]] authentic, honest, and real? I ask that the bio-medical sciences community investigate this compound, the science behind it, and its marketing.<br><br>Coda: A good analysis of GcMAF is available from the Anticancer Fund here.<br><br> | |
| − | * http://scholarlyoa.com/2014/07/24/would-you-take-a-cancer-cure-proven-effective-in-a-predatory-journal/<br>I am writing this blog post in hopes of starting a conversation in the scientific community about the medicine called [[GcMAF]] and one of the companies that is currently distributing it, a company called GcMAF.eu<br><br>[[GcMAF]] means “Gc protein-derived macrophage activating factor,” according to the short article about it on Wikipedia. The drug is currently being marketed as a cure for many ailments, including cancer, autism, MS and Parkinson’s disease.<br><br>I am concerned about this drug and its marketing for these reasons:<br>1. Apparently, some of the same people who are researching the drug also are involved in marketing and selling it.<br>2. Some (not all) of their research has been published in questionable journals, including one published by a publisher that is on my list.<br>3. The drug is not approved by any competent authority (FDA, EMA) to treat any disease.<br><br>The following three articles report favorably on [[GcMAF]] and appear in the American Journal of Immunology a journal published by Science Publications, a publisher on my list. The three articles are:<br>1.Thyer, L., Ward, E., Smith, R., Branca, J. J. V., Morucci, G., Gulisano, M., Noakes, D. & Pacini, S. (2013). Therapeutic effects of highly purified de-glycosylated [[GcMAF]] in the immunotherapy of patients with chronic diseases. American Journal of Immunology, 9(3), 78-84.<ref>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738989/ Article "Therapeutic effects of highly purified de-glycosylated [[GcMAF]] in the immunotherapy of patients with chronic diseases"</ref><br>2.Smith, R., Thyer, L., Ward, E., Meacci, E., Branca, J. J. V., Morucci, G., Gulisano, M. R., | ||
* http://www.anticancerfund.org/fr/news/gcmaf-for-the-treatment-of-breast-cancer-retraction-of-an-article-by-yamamoto-et-al Rétraction d'un article de Yamamto et al. concernant le [[GcMAF]] en tant que traitement du cancer du sein | * http://www.anticancerfund.org/fr/news/gcmaf-for-the-treatment-of-breast-cancer-retraction-of-an-article-by-yamamoto-et-al Rétraction d'un article de Yamamto et al. concernant le [[GcMAF]] en tant que traitement du cancer du sein | ||
Version du 20 août 2015 à 10:18
Marco Ruggiero, né en 1956 à Florence en Italie, est titulaire d'un doctorat en biologie moléculaire, médecin spécialisé en radiologie clinique. Il a été professeur de biologie moléculaire au Département de expérimentale et clinique de sciences biomédicales de l'Université de Firenze (Italie) depuis plus de 20 ans (1992-2014). Depuis 2013, il est Directeur scientifique à Immuno Biotech Ltd, à Guernesey, Iles Anglo-Normandes, Grande-Bretagne[2] dont le directeur est David Noakes.
Négationiste du VIH
Article "Florence, enquête interne au sujet du chercheur «négationniste» qui guérit le SIDA avec du yaourt" Par Alessandro Delfanti, publié le 21 mars 2012 dans Il Fatto Quotidiano[3]
Dans la ligne de mire de l'université florentine, l'activité académique du biologiste moléculaire Marco Ruggiero, connu au niveau international comme faisant partie du petit groupe de chercheurs selon lesquels il n’est pas acquis que le virus Hiv soit la cause du syndrome d'immunodéficience. Une thèse considérée comme très dangereuse par la plupart des experts en la matière.
Il y a quelques jours le recteur Alberto Tesi a ouvert une enquête interne sur les activités académiques de l'un de ses professeurs, le biologiste moléculaire Marco Ruggiero, suite à une lettre reçue d'un groupe de patients et des militants. Ruggiero, en fait, est connu à l'échelle internationale comme faisant partie d’un petit groupe de chercheurs qui nient que le VIH soit la cause du SIDA, une thèse sans fondement et en opposition de celle de la plupart des experts et de la communauté universitaire et médicale.
Ruggiero, selon la lettre envoyée par le groupe de discussion HIV Forum[4], dans ses activités à l'Université de Florence fait des cours négationnistes aux étudiants et est le superviseur de thèses dans la même veine. Il serait, en outre, arrivé à prendre contact avec des patients en réseau en proposant l'utilisation de yaourt additionné de Gc-Maf, une protéine avec des effets "qui renforcent le système immunitaire" et qui permettrait à l'organisme de lutter contre le virus sans l'utilisation de médicaments antirétroviraux: une 'hypothèse irrecevable pour qui fait de la recherche médicale et pour les mêmes patients. La lettre exprime sa "vive inquiétude à propos de la négligence avec laquelle l'Université de Florence semble aborder les théories enseignées et les activités menées par le professeur Marco Ruggiero sur une question d'intérêt vital pour nous: celle du VIH comme cause du SIDA".
En réponse à la lettre demandant de se dissocier des activités du biologiste, l’Université de Florence va enquêter sur "le comportement didactique et la responsabilité" de Ruggiero, comme l'a déclaré un porte-parole interrogé par la revue Nature. Il y a quelques mois Ruggiero avait signé avec le chef de file des négationistes, l'Américain Peter Duesberg, un article scientifique publié dans une revue de l'Université de Florence, l’Italian Journal of Anatomy and Embryology (Ijae). La revue est dirigé par un autre biologiste florentin, le professeur Paul Romagnoli. Dans cet article, il remet en question le rôle du VIH dans l'épidémie du SIDA en Afrique et rabaisse le rôle des médicaments antirétroviraux utilisés pour la combattre.
La guerre aux antirétroviraux menée dans le camp des "négationnistes»" est dangereuse: remettre en question l'efficacité est susceptible de convaincre les patients de ne pas les utiliser. Dans une interview avec Galileo, Stefano Vella, de l’Institut supérieur de la Santé et de la Commission nationale pour la lutte contre le SIDA, souligne que l'étude de Ruggiero "ne mentionne ni les bénéfices produits par ces médicaments en termes d'augmentation de survie et de réduction impressionnante de mortalité, observés à travers les deux essais cliniques contrôlés des études observationnelles [de suivi ?], ni ne cite le fait qu’aujourd'hui l'espérance de vie des patients [entrant] dans le schéma du traitement est comparable à celle des personnes non infectés. C’est le propre de cet effet extraordinaire de la thérapie de démontrer le lien de causalité entre le virus et la maladie”.
La commission d'enquête interne de l'université évaluera les activités éducatives de Ruggiero et se prononcera d’ici le 15 avril prochain. Il n’est pas encore clair si ses décisions pourraient avoir des répercussions sur la carrière académique de Ruggiero. Entre temps, deux membres internationaux du Comité scientifique de la revue de l'Université de Florence ont déjà démissionné. Aucune répercussion par contre sur celui qui la dirige, le professeur Romagnoli.
La suite donnée par l'Université de Florence semble avoir finalement aboutit, après diverses péripéties à une décision de radiation de Ruggiero de l'ordre des médecins et à sa démission le 31 décembre 2014 de l'Université de Florence.
Ruggiero et la GcMAF
Le probiotique Bravo additionné de GcMAF de Ruggiero
Liens externes
- http://scholarlyoa.com/2014/07/24/would-you-take-a-cancer-cure-proven-effective-in-a-predatory-journal/
I am writing this blog post in hopes of starting a conversation in the scientific community about the medicine called GcMAF and one of the companies that is currently distributing it, a company called GcMAF.eu
GcMAF means “Gc protein-derived macrophage activating factor,” according to the short article about it on Wikipedia. The drug is currently being marketed as a cure for many ailments, including cancer, autism, MS and Parkinson’s disease.
I am concerned about this drug and its marketing for these reasons:
1. Apparently, some of the same people who are researching the drug also are involved in marketing and selling it.
2. Some (not all) of their research has been published in questionable journals, including one published by a publisher that is on my list.
3. The drug is not approved by any competent authority (FDA, EMA) to treat any disease.
The following three articles report favorably on GcMAF and appear in the American Journal of Immunology a journal published by Science Publications, a publisher on my list. The three articles are:
1.Thyer, L., Ward, E., Smith, R., Branca, J. J. V., Morucci, G., Gulisano, M., Noakes, D. & Pacini, S. (2013). Therapeutic effects of highly purified de-glycosylated GcMAF in the immunotherapy of patients with chronic diseases. American Journal of Immunology, 9(3), 78-84.[10]
2.Smith, R., Thyer, L., Ward, E., Meacci, E., Branca, J. J. V., Morucci, G., Gulisano, M. R., Ruggiero, M., Pacini, A, Paternostro, F., Di Cesare Mannelli, L., Noakes, D. J., & Pacini, S. (2013). Effects of Gc-macrophage activating factor in human neurons; implications for treatment of chronic fatigue syndrome. American Journal of Immunology, 9(4), 120-129.[11]
3.Ward, E., Smith, R., Branca, J. J. V., Noakes, D., Morucci, G., & Thyer, L. (2014). Clinical Experience of Cancer Immunotherapy Integrated with Oleic Acid Complexed with De-Glycosylated Vitamin D Binding Protein. American Journal of Immunology, 10(1), 23-32.[12]
The first and the third articles report the authors’ experience with patients treated at the Immuno Biotech Treatment Center. From their website one sees that the cost is €6,000 a week for the center, and their hotel cost estimate is €1,800. This price is significantly higher than the €600 they charge for the GcMAF ampule alone. These patients have been an important source of revenue for this company.
As far as I can tell, none of the authors discloses affiliation to this center, so it is not clear who treated the patients. Moreover, there is no other information on this treatment center than the information on these articles and the website of this company. Thus it is rather strange that patients have to have a separate budget for their accommodation, which means there are being treated as outpatients. What is the point on making them travel to receive a treatment that could be given on an outpatient basis by one of the 350 doctors around the world claimed to be using GcMAF?
The publisher of the journal, Science Publications, lists two addresses on its “Contact Us” page, one in Adelaide, SA, Australia and one in New York, NY, USA. I think both addresses are really those of mail-forwarding services and the publisher is hiding its true location, which remains unknown.
Why are these scientists publishing their work in a highly questionable journal operated by a non-transparent publisher? If the work is so groundbreaking (a cure for cancer, et al.), why not publish it in a legitimate journal where its impact would be greater, its conclusions more convincing?
Do any of the authors have any declarable conflicts of interest? If so, what are they? Where can I find them?
On the GcMAF.eu website, the site of the company that sells the potion, under the “Who we are” link, it says this:
We are a group of scientists led by Professor Marco Ruggiero MD, a molecular biologist and fully qualified medical doctor. The team includes a PhD and two BSc biomedical scientists. External doctors, oncologists and scientists kindly provide help and advice. We are committed to bringing GcMAF and its associated treatments to as many people as we can.
Ruggiero is listed as one of the authors of one of the articles above, so I assume the other authors are part of his team and are associated with the company GcMAF.eu.
One of the first scientists to research GcMAF was Nobuto Yamamoto, but his 2007 article on the compound was retracted.
Regarding pricing, the company’s website states
Our GcMAF is €600, plus €60 packing and shipping, for one 2.2ml vial. A vial is one third full and contains up to eight doses – one 100ng, 0.25ml dose a week.
I found the overall tone of the GcMAF website to be mean and self-righteous. It makes a lot of claims such as “Root canals are a major cause of the immune system being suppressed and they are a major cause of cancer.”
Is the published science behind GcMAF authentic, honest, and real? I ask that the bio-medical sciences community investigate this compound, the science behind it, and its marketing.
Coda: A good analysis of GcMAF is available from the Anticancer Fund here. - http://www.anticancerfund.org/fr/news/gcmaf-for-the-treatment-of-breast-cancer-retraction-of-an-article-by-yamamoto-et-al Rétraction d'un article de Yamamto et al. concernant le GcMAF en tant que traitement du cancer du sein
Références
- ↑ http://www.autismone.org/users/marco-ruggiero
- ↑ http://www.autismone.org/users/marco-ruggiero
- ↑ http://www.ilfattoquotidiano.it/2012/03/21/firenze-inchiesta-interna-ricercatore-negazionista-cura-laids-yogurt/198915/
- ↑ http://hivforum.info/forum/viewtopic.php%3Ff%3D22%26t%3D923&usg=ALkJrhiJPcHAxC0p-zGjm782ds2o-8Bdsw#p12548
- ↑ http://oggiscienza.it/2014/08/01/human-brain-project-con-yogurt/ Article "Human Brain Project con yogurt" publié le 1er août 2014 par Sylvie Coyaud sur le site oggiscienza (italien)
- ↑ http://oggiscienza.it/2015/06/25/lodissea-dello-yogurt-continuazione/ La saga de l'ancien médecin Marco Ruggiero, revendeur de yaourt pour traiter le Sida et autres maladies, n'est pas encore finie
- ↑ http://firenze.repubblica.it/cronaca/2015/05/16/news/medico_nego_l_aids_ora_vende_yogurt_anti-cancro_-114526984/ Article publié le 16 mai 2015
- ↑ http://www.firstimmune.fr/gcmaf-products/bravo-probiotic/&usg=ALkJrhgxHDbl09RRRP6bPpkpJTztUSERsg le probiotique Bravo sur le site de First Immune
- ↑ http://www.moneyhouse.ch/it/u/silver_spring_sagl_CH-501.4.019.701-7.htm&usg=ALkJrhg1vd7Jn43hI4QUERvZ8nyroO8jTg Silver Spring Sagl, c/o Fulvia Gianetta Allio, Via Raimondo Rossi 24, 6864 Arzo, appartenant à Marco Ruggiero
- ↑ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738989/ Article "Therapeutic effects of highly purified de-glycosylated GcMAF in the immunotherapy of patients with chronic diseases"
- ↑ http://thescipub.com/PDF/ajisp.2013.120.129.pdf Article "Effects of Gc-macrophage activating factor in human neurons; implications for treatment of chronic fatigue syndrome"
- ↑ http://www.legamberifoods.com/polopoly_fs/1.155809.1411607941!/httpFile/file.pdf Article "Clinical Experience of Cancer Immunotherapy Integrated with Oleic Acid Complexed with De-Glycosylated Vitamin D Binding Protein"
cet article est une ébauche